News and Events


September 2021: Blood tube shortages

There is currently some concern in the NHS about a lack of blood tubes for taking blood tests. This does not apply to cancer patients undergoing treatment or patients on surveillance for possibly development of cancer or recurrence of cancer. Therefore all women diagnosed with any form of gestational trophoblastic disease and any patient with a germ cell tumour registered with our service should continue to do their blood tests as normal. If you experience any problems, please contact us.


January 2021: Molar pregnancy, shielding and COVID vaccination

We are aware that some UK patients are receiving letters suggesting they need to shield after a molar pregnancy. Provided you are not having chemotherapy there is no need to shield any differently from the rest of the population unless there is another reason for you to shield (e.g. you suffer from another condition that puts you at risk). With regards to COVID vaccination, there is no reason from a molar pregnancy point of view why you cannot have the vaccine and if you are offered it then please do have it unless there is another contraindication to having the vaccine. In particular, we are aware that someone in the molar pregnancy group has suggested that COVID vaccination can stop you from getting pregnant. This is not founded on any data or research and government advice is that it is safe for non-pregnant women to have the vaccine.


March 2020: Postal Registrations

We no longer accept postal registrations, clinicians should register their patients online or use the email registration form.


February 2020: Faxes

From March 2020 we will no longer accept or send faxes. Please click here for other ways to contact us.


June 2018: Change in Practice – Post pregnancy hCG follow-up on molar pregnancy patients.

In July 2017 we ceased monitoring any pregnancies subsequent to molar pregnancy in women with a single molar event not requiring chemotherapy. Data analysis shows the risk of developing recurrent/new disease is extremely low at 1:4,110. For women with multiple moles (more than one) and women treated with chemotherapy we continue to monitor.

This data will be published shortly and will be reflected in the forthcoming revised RCOG guidelines.



  • Bi-monthly patient drop-in sessions held in February, April, June, August, October and December each year. Newly diagnosed patients are invited to attend our bi-monthly sessions held at Charing Cross Hospital. For further information please contact the Advisory team on tel: 020 3311 1409
  • The International Society for the Study of Trophoblastic Diseases (the ISSTD) holds biennial symposia for its members. For further details please visit the ISSTD website at
  • Fundraising. If you wish to provide your support and help raise money for research please either see our page detailing forthcoming events or visit our charity website or our webpage on the just giving site.